Timothy Archer - 05 Feb 2025 Form 4 Insider Report for LAM RESEARCH CORP (LRCX)

Role
President and CEO
Signature
Marta Woods by Power of Attorney
Issuer symbol
LRCX
Transactions as of
05 Feb 2025
Net transactions value
$0
Form type
4
Filing time
06 Feb 2025, 16:06:13 UTC
Previous filing
02 Jul 2024
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LRCX Common Stock Options Exercise $0 +86,548 +10% $0.000000 932,940 05 Feb 2025 Direct F1, F2
holding LRCX Common Stock 48,026 05 Feb 2025 By 401(k)
holding LRCX Common Stock 5,670 05 Feb 2025 By Spouse 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRCX Market-based Performance Restricted Stock Unit Options Exercise $0 -152,000 -100% $0.000000 0 05 Feb 2025 Common Stock 152,000 $0.000000 Direct F3
holding LRCX Market-based Performance Restricted Stock Unit 181,020 05 Feb 2025 Common Stock 181,020 $0.000000 Direct F4
holding LRCX Market-based Performance Restricted Stock Unit 147,260 05 Feb 2025 Common Stock 147,260 $0.000000 Direct F5
holding LRCX Employee Stock Option (Right to Buy) 151,980 05 Feb 2025 Common Stock 151,980 $54.06 Direct F6
holding LRCX Employee Stock Option (Right to Buy) 59,970 05 Feb 2025 Common Stock 59,970 $59.88 Direct F7
holding LRCX Employee Stock Option (Right to Buy) 181,020 05 Feb 2025 Common Stock 181,020 $49.09 Direct F8
holding LRCX Employee Stock Option (Right to Buy) 121,400 05 Feb 2025 Common Stock 121,400 $30.03 Direct F9
holding LRCX Employee Stock Option (Right to Buy) 113,300 05 Feb 2025 Common Stock 113,300 $17.68 Direct F10
holding LRCX Employee Stock Option (Right to Buy) 147,240 05 Feb 2025 Common Stock 147,240 $98.15 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On 03/01/2022, the Reporting Person received a target grant of 152,000 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 03/01/2025. The vesting of this award is based on the total return stock price performance of Lam Research shares (assuming reinvestment of dividends) relative to the market price performance of the PHLX Semiconductor Sector Total Return Index, comparing the 50-trading day trailing average closing price over the performance period from 02/01/2022 through 01/31/2025.
F2 The amount reported includes shares subject to unvested restricted stock units.
F3 The Market-based performance restricted stock units will vest between 0% and 150% on 03/01/2025. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Total Return Index Total Shareholder Return during the performance period of 02/01/2022 through 01/31/2025.
F4 The Market-based performance restricted stock units will vest between 0% and 150% on 03/01/2026. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the PHLX Semiconductor Total Return Index Total Shareholder Return during the performance period of 02/01/2023 through 01/31/2026.
F5 The Market-based performance restricted stock units will vest between 0% and 150% on 03/01/2027. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the PHLX Semiconductor Total Return Index Total Shareholder Return during the performance period of 02/01/2024 through 01/31/2027
F6 The stock options will become exercisable in three equal installments on 03/01/2023, 03/01/2024, and 03/01/2025.
F7 The stock options will become exercisable in three equal installments on 03/01/2022, 03/01/2023, and 03/01/2024.
F8 The stock options will become exercisable in three equal installments on 03/01/2024, 03/01/2025, and 03/01/2026.
F9 The stock options will become exercisable in three equal installments on 03/02/2021, 03/02/2022, and 03/02/2023.
F10 The stock options will become exercisable in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022.
F11 The stock options will become exercisable in three equal installments on 03/01/2025, 03/01/2026, and 03/01/2027.

Remarks:

Adjusted to reflect a ten-for-one forward split of the Issuer's common stock effective after market close on October 2, 2024.